Core Viewpoint - SeaStar Medical Holding Corporation (NASDAQ: ICU) is facing allegations of issuing materially false and misleading statements regarding its compliance controls and financial reporting, which may lead to a restatement of financial statements and an overstatement of its business prospects [2]. Group 1 - The class period for the allegations is from October 31, 2022, to March 26, 2024 [2]. - Allegations include deficiencies in compliance controls related to the Humanitarian Device Exemption (HDE) Application and the likelihood of FDA disapproval of the application in its current form [2]. - The company is accused of downplaying the severity of deficiencies in its financial controls and overstating efforts to remediate these issues [2]. Group 2 - SeaStar is likely to restate one or more previously issued financial statements due to improper accounting for certain outstanding warrants and a prepaid forward agreement [2]. - The company's public statements regarding its post-merger business and financial prospects are claimed to be materially false and misleading [2]. - Shareholders are encouraged to register for the class action by September 6, 2024, to monitor the case's progress [3].

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=94063&from=3 CLASS PERI ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SeaStar Medical Holding Corporation due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 6, 2024 [2][3]. Group 1: Allegations Against SeaStar - The complaint alleges that SeaStar and its executives made false and misleading statements regarding compliance controls related to the HDE Application, leading to overstated regulatory prospects [3]. - It is claimed that SeaStar downplayed deficiencies in its financial controls and overstated efforts to remediate these issues, which may result in the need to restate previously issued financial statements [3]. - The allegations suggest that SeaStar's public statements were materially false and misleading at all relevant times, impacting investor trust and stock performance [3]. Group 2: Financial Restatement Announcement - On March 27, 2024, SeaStar announced it would restate its financial statements for the fiscal year ended December 31, 2022, and interim periods ended March 31, 2023, June 30, 2023, and September 30, 2023 [4]. - The restatement is related to the accounting treatment of certain outstanding warrants and a prepaid forward purchase arrangement, with the CEO stating it would not materially impact business operations or cash position [4]. - Following the announcement, SeaStar's stock price fell by $0.04 per share, or 5.41%, closing at $0.70 per share [4].

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in SeaStar Medical Holding Corporation ("SeaStar Medical" or the "Company") (NASDAQ: ICU) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of SeaStar Medical investors who were adversely affected by alleged securities fraud between October 31, 2022 and March 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra- ...

NEW YORK, Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Shareholders who purchased shares of ICU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/seastar-medical-loss-submission-form/?id=93549&from=4 CLASS PERIOD: O ...

Core Viewpoint - SeaStar Medical Holding Corporation is facing a federal securities class action lawsuit due to allegations of making false or misleading statements regarding its compliance controls and financial reporting, leading to a significant restatement of its financial statements [2][3][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against SeaStar and has set a deadline of September 6, 2024, for investors to seek the role of lead plaintiff in the class action [2]. - The lawsuit alleges that SeaStar and its executives violated federal securities laws by failing to disclose deficiencies in compliance controls related to the HDE Application and overstating the regulatory prospects of the SCD [3]. Group 2: Financial Restatement - On March 27, 2024, SeaStar announced it would restate its financial statements for the fiscal year ended December 31, 2022, and interim periods ended March 31, 2023, June 30, 2023, and September 30, 2023, due to issues with the accounting treatment of certain financial instruments [4]. - The CEO stated that the restatement is not expected to materially impact the company's operations or cash position, but is related to non-cash accounting items [4]. Group 3: Market Reaction - Following the announcement of the restatement, SeaStar's stock price fell by $0.04 per share, or 5.41%, closing at $0.70 per share on March 27, 2024 [8].

If you are a shareholder who purchased or otherwise acquired SeaStar securities during the Class Period, you have until September 6, 2024 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained atwww.pomerantzlaw.com. To discuss this action, contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by email are encouraged to include their mailing address, telephone number, and the number of shares ...

Nestor Jaramillo, President and CEO of Nuwellis, shared his thoughts on this milestone: "We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions." About Nuwellis Dr. St ...

NEW YORK, July 25, 2024 /PRNewswire/ -- So what: If you purchased SeaStar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SeaStar and/or Legacy SeaStar had deficient compliance controls and procedures related to the HDE Application; (2) ...

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents inves ...